Azacitidine LA is under clinical development by Nanexa and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Azacitidine LA’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azacitidine LA overview
Azacytidine (NEX-18a) is under development for the treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). It is administered through subcutaneous route in the form of an injection and acts by targeting DNA (cytosine-5-)-methyltransferase 1 (DNMT1). It is a long acting formulation and being developed based on PharmaShell technology.
Nanexa overview
Nanexa is a nanotechnology company that conducts research and development on drug delivery systems. The company offers PharmaShell, a drug delivery system based on containment of microscopic drug particles which creates possibilities for drug release and drug formulations. It provides antifungal coating system that helps in protecting medical products from fungal in-growth. Nanexa’s pharmashell carries out providing longer shelf life of the coated drugs. The company’s low-friction coating finds application in peripheral venous catheters, which provide low friction between the needle and catheter during insertion. It collaborates with defense research agency. Nanexa is headquartered in Uppsala, Sweden.
For a complete picture of Azacitidine LA’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
